Drug Trial Radar · NCT03917381
GEN1046 Safety Trial in Patients With Malignant Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
429
Actual
Start
May 14, 2019
Primary completion
Apr 1, 2025
Study completion Aug 3, 2026
Sponsor
- Lead sponsor
- GenmabIndustry
- Sponsor type
- Industry
- First posted
- Apr 17, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this trial is to learn about the antibody acasunlimab (an antibody also known as GEN1046) when it is used alone and when it is used together with standard of care treatment (docetaxel) or another antibody cancer drug, pembrolizumab (with or without chemotherapy), for treatment of patients with certain types of cancer. All subjects will receive active drug; no one will receive placebo. This trial has 2 parts. The purpose of the first part is to find out if acasunlimab at various doses is safe and to find out the best doses of acasunlimab to use. The purpose of the second part is to give acasunlimab to more subjects to see how well the doses of acasunlimab selected in the first part work against cancer when given alone and how well they work when given with pembrolizumab with or without chemotherapy. Trial details include: * The average trial duration for an individual subject will be about 74 weeks. * The average treatment duration for an individual subject will be about 21 weeks. * The visit frequency will be weekly at first and lessening over time until visits are only once every 3 weeks.
Conditions
- Solid Tumors
Interventions
AcasunlimabBiological
Acasunlimab will be administered intravenously once every 21 days (in selected expansion cohorts acasunlimab will be administered intravenously once every 21 days for the first 2 cycles, and every 42 days in subsequent cycles).
Acasunlimab in combination with docetaxel (in a single expansion cohort)Biological
Acasunlimab and docetaxel will be administered intravenously once every 21 days.
Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)Biological
Acasunlimab and pembrolizumab will be administered intravenously once every 21 days or every 42 days, respectively.
Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)Biological
Acasunlimab and pembrolizumab and standard chemotherapy will be administered intravenously once every 21 days for 4 cycles, followed by treatment with acasunlimab and pembrolizumab once every 21 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLT)Time frame: During first cycle (21 days)
- Dose Escalation and Monotherapy Expansion Cohorts: Number of Participants With Treatment-emergent Adverse Events (AEs)Time frame: Up to approximately 5 years, 10 months
- Expansion Cohort 1: Objective Response Rate (ORR)Time frame: Up to approximately 5 years, 10 months
Locations
57 sites in 10 countries. Site status is shown where the registry gives one.
Mayo Clinic
Phoenix, Arizona
Yale University Cancer Center
New Haven, Connecticut
Mayo Clinic
Jacksonville, Florida
Emory University
Atlanta, Georgia
University of Iowa Hospitals
Iowa City, Iowa
Norton Healthcare Inc
Louisville, Kentucky
University of Michigan
Ann Arbor, Michigan
START Midwest
Grand Rapids, Michigan
Mayo Clinic
Rochester, Minnesota
Washington University School of Medicine
St Louis, Missouri
NYU Langone
New York, New York
UNC Chapel Hill
Chapel Hill, North Carolina
Levine Cancer Institute, Atrium Health
Charlotte, North Carolina
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Fakultni nemocnice Brno
Brno, Czechia
University Hospital Brno
Brno, Czechia
Nemocnice AGEL Ostrava-Vítkovice a.s.
Nový Jičín, Czechia
Fakultni nemocnice Olomouc
Olomouc, Czechia
High Technology Hospital Medcenter
Batumi, Georgia
LLC "TIM - Tbilisi Institute of Medicine"
Tbilisi, Georgia
LTD Consilium Medulla
Tbilisi, Georgia
Tbilisi State Medical University and Ingorovka High Medical Technology University Clinic Ltd
Tbilisi, Georgia
Onkologiai Klinika
Debrecen, Hungary
BKMK Hospital
Kecskemét, Hungary
Pulmonology Hospital Törökbálinti
Törökbálint, Hungary
Rambam Health Care Campus RHCC - Rambam Medical Center
Haifa, Israel
Hadassah Medical Organization HMO - Sharett Institute of Oncology
Jerusalem, Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
Sheba Medical Center, Ramat Gan
Tel HaShomer, Israel
Policlinico San'Orsola
Bologna, Italy
IRCCS - Istituto Europeo di Oncologia IEO
Milan, Italy
Istituto Nazionale Tumori - Fondazione Pascale Italy
Naples, Italy
Azienda Ospedaliero Universitaria di Parma
Parma, Italy
AUSL Romagno-Ravenna
Ravenna, Italy
Policlinico Uni. Campus Bio-Medico
Roma, Italy
Regina Elena National Cancer Institute
Rome, Italy
ASST Sette Laghi "Ospedale di Circolo e Fondazione Macchi "
Varese, Italy
Uniwersyteckie Centrum Kliniczne
Gdansk, Poland
Medpolonia Sp. z o.o.
Poznan, Poland
Specialist Hospital in Prabuty
Prabuty, Poland
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.